Mallinckrodt PLC (NYSE:MNK) has been assigned an average rating of “Hold” from the twenty-three ratings firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $45.37.
MNK has been the topic of several research analyst reports. Piper Jaffray Companies set a $67.00 price objective on Mallinckrodt and gave the stock a “buy” rating in a research note on Saturday, October 21st. Zacks Investment Research raised Mallinckrodt from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Goldman Sachs Group assumed coverage on Mallinckrodt in a report on Thursday, September 28th. They set a “buy” rating and a $55.00 price target for the company. UBS reiterated a “buy” rating and set a $70.00 price target on shares of Mallinckrodt in a report on Wednesday, September 6th. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of Mallinckrodt in a report on Friday, October 6th.
Mallinckrodt (MNK) opened at $21.15 on Friday. The firm has a market capitalization of $2,082.51, a price-to-earnings ratio of 2.96, a P/E/G ratio of 0.40 and a beta of 1.46. Mallinckrodt has a 52-week low of $19.00 and a 52-week high of $57.16. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 1.08.
In other Mallinckrodt news, VP Steven J. Romano bought 2,000 shares of Mallinckrodt stock in a transaction on Monday, November 13th. The stock was acquired at an average cost of $21.96 per share, with a total value of $43,920.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Michael-Bryant Hicks bought 7,900 shares of Mallinckrodt stock in a transaction on Thursday, November 9th. The shares were acquired at an average cost of $20.80 per share, with a total value of $164,320.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 30,460 shares of company stock valued at $659,486. 0.53% of the stock is owned by insiders.
Several large investors have recently modified their holdings of the stock. Sterling Capital Management LLC bought a new stake in shares of Mallinckrodt in the 2nd quarter valued at about $204,000. Shelton Capital Management acquired a new stake in Mallinckrodt during the 3rd quarter valued at approximately $205,000. Advisor Partners LLC acquired a new stake in Mallinckrodt during the 2nd quarter valued at approximately $242,000. Municipal Employees Retirement System of Michigan lifted its stake in Mallinckrodt by 24.5% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 5,640 shares of the company’s stock valued at $253,000 after acquiring an additional 1,110 shares during the period. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Mallinckrodt during the 2nd quarter valued at approximately $260,000. Hedge funds and other institutional investors own 97.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Mallinckrodt PLC (MNK) Given Average Recommendation of “Hold” by Brokerages” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/01/mallinckrodt-plc-mnk-given-average-recommendation-of-hold-by-brokerages.html.
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.